Kornimate/medical-research-clean huggingface dataset:
weekly doxycycline dot for sti prevention among cisgender women taking hiv prep in kisumu, kenya

Conditions: STI

Summary: the first study of doxycycline postexposure prophylaxis for cisgender women did not reduce incident stis likely due to low use of doxycycline. researchers will conduct a pilot study of once-weekly doxyxycline to prevent bacterial stis among kenyan cisgender women using prep for hiv prevention.

a study evaluating doxycycline prophylaxis to prevent sexually transmitted infections (stis) in prep-taking african women, who are a priority population for sti prevention, given their high risk and engagement in longitudinal prevention services. the primary study objective is to assess the acceptability of once weekly doxycycline prophylaxis and assess persistence in once weekly doxycycline delivered as directly observed therapy (dot). sti prophylaxis carries substantial potential benefits but also important potential risks, and we have framed our work as capturing key data to inform this question. researchers hypothesize that weekly doxycycline will substantially reduce the incidence of curable stis, particularly c. trachomatis, the most common bacterial sti and the one responsible for greatest morbidity. researchers' secondary study objectives are to evaluate the impact on incidence rate of stis in women given once-weekly doxycycline dot in comparison with data collected among participants assigned to received standard of care in recently completed dpep kenya study as well as to assess tolerability of once weekly doxycycline prophylaxis. researchers will collect samples for future doxycycline hair drug level testing, antibiotic resistance testing, and microbiome evaluation.

Eligibility criteria:
inclusion criteria: 1. willing and able to give written informed consent 2. age 18-30 years 3. female sex assigned at birth 4. hiv-seronegative, according to national hiv testing algorithm 5. has a current prescription for prep, \> 1 month, according to the national guidelines of kenya exclusion criteria: 1. pregnant 2. breastfeeding a child 3. allergy to tetracycline class 4. current medications which may impact doxycycline metabolism or that are contraindicated with doxycycline, as per the prescribing information. these include systemic retinoids, barbiturates, carbamazepine, phenytoin, and warfarin. 5. active, clinically significant medical or psychiatric conditions that would interfere with study participation, at the discretion of the site investigator or designee. 6. prior enrollment in the dpep kenya study

Keywords: sti
sodium restriction in the management of cirrhotic ascites

Conditions: Ascites

Summary: to determine the relationship between degree of sodium restriction and dietary compliance with clinical outcome of diuresis of portal hypertensive ascites in cirrhotic patients from a county hospital population. primary objective: demonstrate that, when accompanied by the appropriate diuretic regimen, a no added salt diet (4 grams sodium per day) is as effective as a low sodium diet (2 grams sodium per day) in the management of cirrhotic ascites.

secondary objectives: 1. demonstrate that patient acceptance is greater and diuresis faster with a no added salt diet compared with a low sodium diet 2. demonstrate that side-effects of diuretic therapy are the same or less when patients are on a no added salt diet 3. determine if glomerular filtration rate estimated from the modified diet in renal disease equation differs from that obtained by a 24 hour urinary creatinine in patients with cirrhotic ascites

Eligibility criteria:
inclusion criteria: * cirrhotic patients of any etiology with ascites from portal hypertension diagnosed by paracentesis, * age 18-75 * clinical or radiographic (abdominal ct or ultrasound) estimate of moderate - severe ascites * spanish-speaking subjects will be eligible for participation exclusion criteria: * active drug or alcohol abuse, * active complications of sbp, hepatic encephalopathy, or gi bleed within 2 weeks, * hemorrhagic ascites, malignant ascites, * creatinine \>2 mg/dl or ccl \< 30 ml/min, * k \> 5.5 mmol/l, * diuretic refractory ascites * allergy to or intolerance of either spironolactone or furosemide * homelessness, incarceration, inability to follow up in clinic, or comply with diet.

Keywords: cirrhosis portal hypertension ascites sodium restriction
whole body vibration - a new therapeutic approach to improve muscle function in cf

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to evaluate the effects of whole body vibration (wbv) on muscle function in adult cf-patients.

cystic fibrosis (cf) is the most common chronic hereditary disease in caucasians. due to improved therapy and better understanding of the disease, life expectancy has risen to an average of 38 years and is continuing to rise. with the increased life-expectancy it becomes even more important to maintain functional activity as part of quality of life. mechanical stimulation in form of whole body vibration (wbv) is a new type of exercise currently tested in sports, geriatrics and rehabilitation. it has recently been found to be a safe and efficient method to activate muscular activity via stretch reflexes leading to improvement of muscular performance, body balance and physical functioning. 10 patients of the cf center cologne, germany, took part in the galileo study. they were provided by the vibrating platform (galileo 2000)for whole body vibration training at home. the patients were standing in an upright position receiving vertical vibration of frequencies between 20-25 hz. this vibration exercise evokes muscle contractions via stretch reflexes improving muscular activity. the training schedule consisted of three 3-minute sessions twice a day 5 days per week for 3 months. every 4 weeks the patients were seen for assessment of muscle function to evaluate the effects of this new intervention.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of cystic fibrosis * age older than 18 years exclusion criteria: * hypersplenic syndrome * acute arthritis or osteomyelitis

Keywords: whole body vibration muscle function cystic fibrosis mechanography chair-rising-test
super-hypofractionated partial breast irradiation

Conditions: Breast Cancer; Radiotherapy Side Effect

Summary: partial breast irradiation is currently a hot topic in clinical research, but the appropriate population and appropriate irradiation the technology and dose fractionation mode are still inconclusive. foreign studies have mostly selected patients with low risk of recurrence. breast-conserving surgeries for early-stage breast cancer are increasing year by year in china. it is necessary to conduct prospective clinical studies to explore the chinese population suitable for partial breast irradiation and the appropriate radiotherapy dose fractionation model. a preliminary study in our center has compared the safety and efficacy of a 2-week schedule of partial breast irradiation (40gy/10f) and a 3-week schedule of whole-breast radiotherapy (43.5gy/15f) in patients with early-stage low-risk breast cancer after breast-conserving surgery. , preliminary results show that the 2-week partial breast irradiation regimen is safe and effective. this study plans to continue to select low-risk breast-conserving patients, use extracorporeal intensity-modulated radiotherapy technology, refer to the radiotherapy dose fractionation model of the fast-forward study, and give partial breast irradiation 5.2 gy/f/d, a total of 5 times, with a total dose of 26gy, to further shorten the time the radiotherapy time is 1 week, and the acute and late adverse reactions of radiotherapy and the local control of the tumor are prospectively observed. provide evidence for conducting a national multi-center phase iii clinical randomized study.


Eligibility criteria:
inclusion criteria: 1. ≥45 years old, \<75 years old women 2. life expectancy \>5 years 3. start radiotherapy within 12 weeks after breast-conserving surgery (or within 8 weeks from the end of chemotherapy) 4. invasive ductal carcinoma grade 1-2, or mucinous carcinoma, papillary carcinoma, canalicular carcinoma, medullary carcinoma; primary tumor ≤3.0cm; both pn0 (axillary dissection or sentinel lymph node biopsy) 5. low-risk dcis: tumor ≤2.5cm, low to medium grade; axillary surgery is not required or pn0 6. single focus (with mri diagnosis) 7. vascular tumor thrombus negative 8. er and/or pr positivity (defined as strong positivity in \>1% of tumor cell nuclei) 9. negative pathological margin≥2mm 10. place metal markers on the tumor bed 11. sign the informed consent form exclusion criteria: 1. multiple primary tumors 2. invasive ductal carcinoma grade 3 3. invasive micropapillary carcinoma 4. lobular carcinoma in situ 5. invasive lobular carcinoma 6. simple nipple paget's disease 7. oncoplastic surgery 8. neoadjuvant chemotherapy or neoadjuvant endocrine therapy 9. previous or simultaneous contralateral breast cancer 10. history of ipsilateral chest wall radiotherapy 11. have active collagen vascular disease
balloon induction of labor in prom for tolac

Conditions: Previous; Cesarean Section, Cicatricial, Complicating Pregnancy or Childbirth, Affecting Fetus or Newborn; Prelabor Rupture of Membranes

Summary: a prospective randomized controlled trial to evaluate the safety and efficacy of labor induction with a double balloon catheter (atad ripener device) in women desiring tolac (trial of labor after cesarean) with prom (pre labor rupture of membranes).


Eligibility criteria:
inclusion criteria: only patients who meet the following criteria will be approached. 1. singleton pregnancy 2. previous single cesarean section 3. at least 12 months have elapsed since the previous caesarean delivery 4. diagnosed with confirmed prom at ≥ 34 weeks' gestation. 5. ruptured membranes have occurred ≤24 hours prior to inclusion in the study. 6. vertex presentation well applied to the cervix 7. found to have an unripe cervix in a speculum examination (bishop score ≤6). 8. absence of significant and regular uterine contraction (\<3/10min). 9. willingness to comply with the protocol for the duration of the study. 10. have signed an informed consent (including a tolac consent form). exclusion criteria: patients having any of the following conditions will be excluded from the study: 1. any contraindication for a vaginal delivery (i.e. placenta previa, non-vertex presentation, previous cesarean delivery \< 12 months). 2. regular uterine contractions (\>3/10min). 3. diagnosis of ruptured membranes was made over 24 hours prior to study inclusion. 4. meconium stained amniotic fluid. 5. evidence of chorio-amnionitis (t 37.6°c with uterine tenderness and maternal or fetal tachycardia or purulent discharge or wbc20.000) 6. suspected placental abruption or a significant hemorrhage. 7. non-reassuring fetal status (as determined by fetal heart rate monitoring and/or bio-physical profile) necessitating immediate intervention.

Keywords: induction of labor previous cesarean delivery trial of labor after cesarean prelabor rupture of membranes balloon induction
effect of dapagliflozin on cardiac structure, function and secondary mitral regurgitation in patients with left ventricle dysfunction

Conditions: Dilated Cardiomyopathy

Summary: a significant reduction in the incidence of cv death or hospitalization for hf has been observed in randomized trials investigating the cv benefit of dapagliflozin. mechanistic investigations are required to interpret the positive clinical effects of dapagliflozin on heart structure and valvular regurgitation.

a functional mitral regurgitation (mr) occurs when the mitral valve (mv) becomes tethered due to abnormal lv remodelling in individuals with heart failure (hf) and left ventricular (lv) dilatation. the primary treatment for hf is medical, and it is based on established guidelines, as lv failure is the most common cause of secondary functional mr. standard medical therapy for patients with functional mr, including beta blockers, ace inhibitors, and angiotensin receptor blockers (arb), does not reduce the morbidity or mortality associated with these conditions. similar to the neprilysin inhibitor, which promotes sodium excretion and has vasodilatory effects via relaxing blood vessels, dapagliflozin reduce cardiac preload and afterload by inducing natriuresis and reducing arterial stiffness. effects on blood pressure reduction and weight loss may also positively affect left ventricular (lv) remodelling. using echocardiography, researchers hope to test the hypothesis that dapagliflozin improves mr in patients with functional mr due to lv dysfunction. this hypothesis is based on studies showing the beneficial effects of dapagliflozin on lv modelling.

Eligibility criteria:
inclusion criteria: * outpatients ≥ 18 years of age * dilated lv with a reduced ejection fraction and secondary functional mr * nyha functional class ii or iii * moderate to severe mr which lasted \> 6 months under medical treatment with a β-blocker and an ace inhibitor (or arb) exclusion criteria: * current use or prior use of dapagliflozin * current acute heart failure or prior admission with acute decompensated heart failure in 6 months before entry to study * nyha functional class iv * chronic renal impairment with gfr \< 30 ml/min/1.73m2 * pregnant or lactating women * history of allergy to dapagliflozin
lithium disilicate (cad/cam) fixed partial dentures (fpd) clinical study

Conditions: Missing Tooth

Summary: this investigation will be a clinical trial to study the performance of a high strength ceramic material for bridges to replace missing teeth. the ceramic material has been approved by the fda for patient treatment. a computer technique will be used to make the bridges. the bridges will be cemented using an adhesive resin cement (multilink automix/ivoclar). the bridges are planned be evaluated for clinical performance at 6 months, 1 year, 2 years, 3 years, and if funding permits, 4 years, and 5 years. the purpose of the study is to measure how well the high strength bridges function over an extended period of time.

the study will be composed of 30 bridges placed in adult patients that have been identified as requiring replacement of a single tooth. all the bridges will be made from the same high strength ceramic material (emaxcad/ivoclar) using a computer to make the entire bridge. all the crowns will be cemented using the most current marketed version of the manufacturer's adhesive resin cement (multilink automix/ivoclar). at each recall appointment an evaluation of the bridge will be completed as well as clinical photographs, an intraoral digital scan, and impression of the bridge. the purpose of the study is to measure how well the high strength bridges function over an extended period of time.

Eligibility criteria:
inclusion criteria: * missing one anterior or premolar tooth that is appropriate for replacement with a bridge. the second premolar tooth will be the most distal tooth acceptable as a pontic for inclusion in the study. * healthy periodontal status for the adjacent abutment teeth with 1:1 crown:root ratio * abutment teeth must be asymptomatic prior to treatment * endodontically treated teeth will be acceptable for abutments as long as nonmetallic cores can be placed to retain the fpd since the lithium disilicate will be bonded to the abutments. * no more than one bridge will be placed per patient. if a patient presents with more than one missing teeth acceptable for the study, premolar teeth will be included prior to anterior teeth. each bridge will be three units and include only one missing tooth. exclusion criteria: * sensitive abutment teeth * teeth with a history of direct or indirect pulp capping procedures * patients with significant untreated dental disease to include periodontitis and caries * pregnant or lactating women * patients with allergies to any material in the study * patients unable to return for recall appointments
reducing falls with progressive resistance training for the oldest old adults with sarcopenia

Conditions: Sarcopenia; Aging

Summary: this study will investigate the effects of 12 months of high-intensity progressive resistance training compared with a control group on fall-rate in older adults with sarcopenia.

despite the wealth of theoretical benefits, existing literature on resistance training for falls prevention is not conclusive, given the sub-optimal resistance training paradigms, poor study quality, and use of multimodal training interventions, precluding isolation of the resistance training benefits. it is also possible that resistance training benefits for falls reduction will be most evident in those with sarcopenia to begin with as a risk factor for their falls. we will therefore conduct a randomised, controlled trial assessing the effects of resistance training reduce falls in the oldest old adults with sarcopenia, as well as to increase strength and muscle mass.

Eligibility criteria:
inclusion criteria: * aged 80 years or older * low muscular strength (grip strength: \ 15 seconds) * community-dwelling incl. independent senior housing * ambulatory without supervision or physical assistance from another person. assistive devices such as canes/crutches/walkers allowed. * able to see and hear sufficiently to undertake assessments and partake in the planned exercise training. exclusion criteria: * pre-existing diagnosis of dementia * moderate or severe cognitive impairment (score \<18 on the mini-mental state examination) * living in institutional care * non-ambulatory or requiring person or wheelchair to assist when walking * degenerative neurological and neuromuscular disease/disorder significantly influencing gait and mobility (e.g. amyotrophic lateral sclerosis \[als\] and parkinson's disease). * amputation (other than toes) * contraindications to resistance training * unstable fracture * inability to comply with study requirements * currently undertaking progressive resistance training
mental simulations and early mobilization of patients after cesarean section

Conditions: Anxiety; Cesarean Section

Summary: mental simulations can motivate patients for their first verticalization after cesarean section, although perceived anxiety before verticalization may reduce a positive effect of mental simulations.


Eligibility criteria:
inclusion criteria: * must be qualified to and undergoing delivery using cesarean section, * must be undergoing conduction of anesthesia during cesarean section, * must be undergoing the analgesic therapy in the postoperative period, * must be qualified to mobilization by the medical staff, * must be fluent in polish in speaking and writing. exclusion criteria: * any orthopedic dysfunction, * any neurological dysfunction, * any psychiatric disease.

Keywords: mental simulation anxiety verticalization obstetrics cesarean section post-operative care
a prospective study of apatinib plus concurrent neoadjuvant chemoradiotherapy for siewert ii ，iii of locally advanced her-2 negative adenocarcinoma at gastroesophageal junction

Conditions: Gastroesophageal Junction Adenocarcinoma

Summary: the purpose of this study is to assess the efficacy and safety of patients who receive concurrent neoadjuvant chemoradiotherapy for siewert ii ，iii of locally advanced her-2 negative adenocarcinoma at gastroesophageal junction.


Eligibility criteria:
inclusion criteria: 1. age:18 to 70 years old (man or female); 2. conﬁrmed to siewert ii , iii of locally advanced adenocarcinoma at gastroesophageal junction and tumor long diameter ≤8 cm by gastroscopy and ct, the her-2 negative was detected by immunohistochemistry; 3. patients with stage for ⅲ by ct/mri (according to the eighth edition of ajcc ); 4. patients with measurable lesions(measuring≥10mm on spiral ct scan, satisfying the criteria in recist1.1); 5. eastern cooperative oncology group (ecog) performance status of 0-1; 6. major organ function has to meet the following certeria: hb≥80g/l; anc≥1.5×109/l; plt≥90×109/l; alt and ast≤2.5×uln, but\<≤5×uln if the transferanse elevation is due to liver metastases； tbil\<1.5×uln； serum creatinine ≤1.5×uln; 7. life expectancy greater than or equal to 6 months; 8. women of childbearing age must have contraceptive measures or have test pregnancy (serum or urine) enroll the study before 7 days, and the results must be negative, and take the methods of contraception during the test and the last to have drugs after 8 weeks. men must be contraception or has sterilization surgery during the test and the last to have drugs after 8 weeks; 9. participants were willing to join in this study, and written informed consent, good adherence, cooperate with the follow-up. exclusion criteria: 1. allergic to apatinib, capecitabine and oxaliplatin; 2. the cytological examination of the abdominal cavity washing fluid showed that the tumor shedding cells were positive; 3. have high blood pressure and antihypertensive drug treatment can not control (systolic blood pressure \> 140 mmhg, diastolic blood pressure \> 90 mmhg), uncontrolled coronary heart disease and arrhythmia ,classⅲ-ⅳcardiac insufficiency; 4. a variety of factors influencing oral drugs (such as unable to swallow, nausea, vomiting, chronic diarrhea and intestinal obstruction, etc); 5. patients with tendency of gastrointestinal bleeding, including the following: a local active ulcerative lesions, and defecate occult blood (+ +); has melena and hematemesis in two months; 6. coagulant function abnormality (inr \> 1.5 uln, aptt \> 1.5 uln), with bleeding tendency; 7. pregnant or lactating women; 8. patients with other malignant tumors within 5 years (except for curable skin basal cell carcinoma and cervical carcinoma in situ); 9. history of psychiatric drugs abuse and can't quit or patients with mental disorders; 10. less than 4 weeks from the last clinical trial; 11. the researchers think inappropriate.
plasma lipoprotein response to glucagon-like peptide-2

Conditions: Hyperlipidemias

Summary: some of the fat (triglyceride) from the food humans eat gets stored in the bowel. this triglyceride can then be released into the blood when another meal is consumed or in response to hormones. how the gut hormone glucagon-like peptide-2 (glp-2) releases the triglyceride from the gut is not known. the research team in this study is interested in finding out how teduglutide (a degradation resistant form of glp-2) releases stored triglyceride from the gut by evaluating how blood lipoproteins respond to teduglutide in healthy individuals.

the lipoprotein response will be performed in 15 healthy individuals recruited by newspaper advertisements. each subject will be their own control, receiving both placebo and teduglutide, administered on separate occasions. a member of the study team will explain the study in detail on visit 1, and if the individual is interested in participating, informed consent will be obtained and preliminary screening will occur on visit 2. on visit 3 \& 4 participants will receive a high fat liquid meal after an overnight fast. hourly blood samples will be taken for 5 hours, followed by randomized assignment to receive either subcutaneous placebo or teduglutide at visit 3 and the opposite treatment at visit 4. following the injection, blood samples will be taken every 15 minutes for the first hour and every 30 minutes for the subsequent 3 hours.

Eligibility criteria:
inclusion criteria: * men and women, aged 18 to 60 years. * body mass index 20 to 27 kg/m2 exclusion criteria: * patients with active inflammatory bowel disease * patients with pre-existing celiac disease, exocrine pancreatic insufficiency or small bowel malabsorption * patients with active bowel malignancy * patients with diabetes mellitus or known/ suspected motility disorders of the gut * patients with decompensated liver disease * patients on ezetimibe or bile acid sequestrants * patients who are pregnant or breastfeeding. * patients with renal disease. * patients on benzodiazepine. * unstable cardiac or respiratory disease * any changes to medication in the preceding month

Keywords: intestinal lipoprotein gut peptide chylomicrons